OEM#: L5B4974New OEM Original Outright
PERITONEAL DIALYSIS SOLUTION EXTRANEAL 2L SINGLE BAG CONTAINER 7.5% ICODEXTRIN by Vantive US Healthcare LLC
Your price:
$683.86 Per package of 6
OEM#: L5B4974PERITONEAL DIALYSIS SOLUTION EXTRANEAL 2L SINGLE BAG CONTAINER 7.5% ICODEXTRIN by Vantive US Healthcare LLC
New OEM Original Outright
Your price:
$683.86 Per package of 6
Solution, Peritoneal Dialysis, Extraneal Type, Single Bag (Ambu-Flex II) Container Type, 7.5% Icodextrin Active Ingredient, Automated Peritoneal Dialysis Therapy Type, 2L Capacity
Asset Information
Are you an existing customer? Sign in to access your account.
ADD TO LIST
Product Overview
EXTRANEAL (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. EXTRANEAL is also indicated to improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (PET).Reduces glucose exposure over time and its associated complicationsMay result in improved fluid balanceLonger sustained PD success
Features
- Reduces glucose exposure over time and its associated complications
- May result in improved fluid balance
- Longer sustained PD success
Technical Specs
P/N: L5B4974 Key Specs
Item
PERITONEAL DIALYSIS SOLUTION EXTRANEAL 2L SINGLE BAG CONTAINER 7.5% ICODEXTRIN
OEM
Vantive US Healthcare LLC
OEM #
L5B4974
Condition
New OEM Original
Returnable
No
Warranty
Mfr Warranty
Active Ingredients
7.5% Icodextrin
Container Type
Single Bag (Ambu-Flex II)
Fill Volume
2L
Type
Automated Peritoneal Dialysis, Extraneal
Equivalents
EXTRANEAL (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. EXTRANEAL is also indicated to improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (PET).Reduces glucose exposure over time and its associated complicationsMay result in improved fluid balanceLonger sustained PD success
- L5B4974: Baxter Healthcare Corp.: OEM Acquisition
Product Overview
EXTRANEAL (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. EXTRANEAL is also indicated to improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (PET).Reduces glucose exposure over time and its associated complicationsMay result in improved fluid balanceLonger sustained PD success
Features
- Reduces glucose exposure over time and its associated complications
- May result in improved fluid balance
- Longer sustained PD success
Technical Specs
P/N: L5B4974 Key Specs
Item
PERITONEAL DIALYSIS SOLUTION EXTRANEAL 2L SINGLE BAG CONTAINER 7.5% ICODEXTRIN
OEM
Vantive US Healthcare LLC
OEM #
L5B4974
Condition
New OEM Original
Returnable
No
Warranty
Mfr Warranty
Active Ingredients
7.5% Icodextrin
Container Type
Single Bag (Ambu-Flex II)
Fill Volume
2L
Type
Automated Peritoneal Dialysis, Extraneal
Equivalents
EXTRANEAL (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. EXTRANEAL is also indicated to improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (PET).Reduces glucose exposure over time and its associated complicationsMay result in improved fluid balanceLonger sustained PD success
- L5B4974: Baxter Healthcare Corp.: OEM Acquisition
Product Overview
EXTRANEAL (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. EXTRANEAL is also indicated to improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (PET).Reduces glucose exposure over time and its associated complicationsMay result in improved fluid balanceLonger sustained PD success
Features
- Reduces glucose exposure over time and its associated complications
- May result in improved fluid balance
- Longer sustained PD success
Technical Specs
P/N: L5B4974 Key Specs
Item
PERITONEAL DIALYSIS SOLUTION EXTRANEAL 2L SINGLE BAG CONTAINER 7.5% ICODEXTRIN
OEM
Vantive US Healthcare LLC
OEM #
L5B4974
Condition
New OEM Original
Returnable
No
Warranty
Mfr Warranty
Active Ingredients
7.5% Icodextrin
Container Type
Single Bag (Ambu-Flex II)
Fill Volume
2L
Type
Automated Peritoneal Dialysis, Extraneal
Equivalents
EXTRANEAL (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. EXTRANEAL is also indicated to improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (PET).Reduces glucose exposure over time and its associated complicationsMay result in improved fluid balanceLonger sustained PD success
- L5B4974: Baxter Healthcare Corp.: OEM Acquisition